Key result
Apraclonidine-confirmed Horner syndrome is linked to ~88% lower odds of identifying an underlying cause.
Why the study?
Prior reports differed on whether Horner syndrome is most often caused by tumors and stroke or by neck and chest surgical procedures, potentially due to disparate case accrual methods.
Does pharmacologic confirmation with apraclonidine 0.5% influence the likelihood of identifying an underlying cause and the distribution of etiologies in patients diagnosed with Horner syndrome compared to clinical diagnosis alone?
Cohort (n=318)
No
Does pharmacologic confirmation with apraclonidine 0.5% influence the likelihood of identifying an underlying cause and the distribution of etiologies in patients diagnosed with Horner syndrome compared to clinical diagnosis alone?
Answers are grounded in this paper and cite their sources.
The etiology of Horner syndrome varies by diagnostic accrual method, with surgical/neck procedures being the most common identifiable cause overall, while newly diagnosed Horner syndrome without a known preceding cause warrants vascular and thoracic/neck imaging to rule out occult carotid dissection and tumors.
BACKGROUND: Some reports have indicated that when a cause for Horner syndrome can be determined, it is most often chest and neck tumors and stroke. Others have suggested that Horner syndrome is more frequently caused by surgical procedures in the neck and chest. These differences may be explained by disparate accrual methods. Therefore, we decided to compare the cause of Horner syndrome in cases where the diagnosis was confirmed by apraclonidine testing conducted by ophthalmologists to cases in which the diagnosis was made entirely on clinical grounds mostly by nonophthalmologists. METHODS: We applied a new search engine to the inpatient and outpatient electronic medical records text at the University of Michigan Medical Center from 1996 to 2018 for Horner syndrome with and without pharmacologic confirmation through ocular instillation of apraclonidine 0.5%. Among apraclonidine-confirmed cases, 159 met inclusion criteria. Among apraclonidine-unconfirmed cases, more than 2,000 cases were identified, so that we included only the first 159 cases that met inclusion criteria. In these 318 cases, we documented patient demographics, ophthalmologic features, imaging, underlying cause, and whether the cause was discovered before or after the diagnosis of Horner syndrome. RESULTS: In the cohort of 159 apraclonidine-confirmed cases of Horner syndrome, a cause was identified in 97 (61%). Procedures in the neck, chest, skull base, and paraspinal region accounted for most of the identified causes, with cervical carotid dissection the next most common cause. In a cohort of 159 cases of Horner syndrome not tested with apraclonidine because the clinical diagnosis appeared firm, procedures again accounted for the largest percentage, but tumor was the next most common cause. In both groups, when a cause for Horner syndrome could be identified, that cause was nearly always known before Horner syndrome was identified. However, in an important minority of cases, mostly involving carotid dissection or tumor, the identification of Horner syndrome was critical to the discovery of those conditions. CONCLUSIONS: The prevalence of causes of Horner syndrome depends on the accrual method. Among pharmacologically-confirmed cases, the cause was often undetermined or due to a preceding neck or chest procedure. Among pharmacologically-unconfirmed cases, a substantial proportion had also been caused by neck and chest procedures, but tumors in that region were also common. When a cause of Horner syndrome was found in both cohorts, it was usually known before Horner syndrome was discovered, making Horner syndrome an afterthought. However, in an important minority of cases where the cause was not yet known, the identification of Horner syndrome was valuable in leading to important diagnoses such as carotid dissection and tumor.
No takes yet. Share an insight, caveat, or question.
Sabbagh et al. (2019) conducted a cohort in Horner syndrome (n=318). Pharmacologic confirmation with topical apraclonidine 0.5% vs. Clinical diagnosis without pharmacologic confirmation was evaluated on Identification of an underlying cause for Horner syndrome (OR 0.12, 95% CI 0.06-0.24, p=<0.001). Apraclonidine-confirmed Horner syndrome was associated with lower odds of identifying an underlying cause compared to clinically diagnosed cases.
Synapse has enriched 10 related papers. Consider them for comparative context: